Diagnosed 0 9 0 9 O
with 10 14 10 14 O
advanced 15 23 15 23 B-cancer
or 24 26 24 26 I-cancer
metastatic 27 37 27 37 I-cancer
malignancy 38 48 38 48 I-cancer

Prior 0 5 49 54 O
treatment 6 15 55 64 O
with 16 20 65 69 O
an 21 23 70 72 O
antiPD1 24 31 73 80 B-treatment
, 31 32 80 81 O
antiPDL1 33 41 82 90 B-treatment
, 41 42 90 91 O
antiPDL2 43 51 92 100 B-treatment
, 51 52 100 101 O
antiCD137 53 62 102 111 B-treatment
, 62 63 111 112 O
or 64 66 113 115 O
antiCTLA4 67 76 116 125 B-treatment
antibody 77 85 126 134 I-treatment
, 85 86 134 135 O
or 87 89 136 138 O
any 90 93 139 142 O
other 94 99 143 148 O
antibody 100 108 149 157 O
or 109 111 158 160 O
drug 112 116 161 165 O
specifically 117 129 166 178 O
targeting 130 139 179 188 O
Tcell 140 145 189 194 O
co 146 148 195 197 O
- 148 149 197 198 O
stimulation 149 160 198 209 O
or 161 163 210 212 O
checkpoint 164 174 213 223 O
pathways 175 183 224 232 O

Received 0 8 233 241 O
standard 9 17 242 250 B-treatment
of 18 20 251 253 I-treatment
care 21 25 254 258 I-treatment
treatment 26 35 259 268 I-treatment
for 36 39 269 272 O
primary 40 47 273 280 O
malignancy 48 58 281 291 B-cancer
and 59 62 292 295 O
standard 63 71 296 304 O
of 72 74 305 307 O
care 75 79 308 312 O
treatment 80 89 313 322 O
for 90 93 323 326 O
relapsed 94 102 327 335 O
cancer 103 109 336 342 B-cancer

Subjects 0 8 343 351 O
with 9 13 352 356 O
an 14 16 357 359 O
active 17 23 360 366 O
, 23 24 366 367 O
known 25 30 368 373 O
, 30 31 373 374 O
or 32 34 375 377 O
suspected 35 44 378 387 O
autoimmune 45 55 388 398 B-chronic_disease
disease 56 63 399 406 I-chronic_disease

